Proton Pump Inhibitor Selection and Usage

Introduction to PPI Potency and Efficacy

The American Gastroenterological Association recommends esomeprazole 20-40 mg twice daily or rabeprazole 20-40 mg twice daily as the preferred PPIs due to their superior potency, with pantoprazole specifically recommended to be avoided 1, 2, 3

Rabeprazole 20 mg is equivalent to 36 mg omeprazole, indicating its high potency 1, 2, 3
Esomeprazole 20 mg is equivalent to 32 mg omeprazole, showing its strong acid suppression capability 1, 2, 3
Lansoprazole 30 mg is equivalent to 27 mg omeprazole, demonstrating moderate potency 1, 2, 3
Pantoprazole 40 mg is equivalent to only 9 mg omeprazole, making it the weakest option 1, 2, 3

The American College of Gastroenterology recommends using esomeprazole 40 mg twice daily or rabeprazole 40 mg twice daily in combination regimens for H. pylori eradication, as higher-potency PPIs produce optimal outcomes, especially with amoxicillin-containing regimens 1, 2, 3

Omeprazole 20 mg twice daily is the only PPI formally assessed for EoE treatment, achieving a 50.8% clinicopathological response versus 35.8% with standard/low-dose regimens 4, 5

For severe erosive esophagitis, higher potency PPIs like esomeprazole or rabeprazole may be considered, although cost considerations may outweigh modest clinical superiority over double-dose standard PPIs 6, 7

Twice-daily dosing is superior to increasing once-daily dose strength, with higher doses producing no further benefit 1
Pantoprazole should be avoided when higher acid suppression is needed due to its dramatically lower potency 1, 2, 3
The 2024 AGA guidance emphasizes that potassium-competitive acid blockers (P-CABs) should generally not be used as first-line therapy due to cost, access barriers, and limited long-term safety data, despite modest clinical advantages 7, 6

When cost is equivalent between agents, esomeprazole 20-40 mg twice daily or rabeprazole 20-40 mg twice daily should be selected due to their superior potency 1, 2

The American Gastroenterological Association recommends that for mild erosive esophagitis (Grade A/B), standard-dose PPIs are generally adequate, though esomeprazole or rabeprazole may be considered in selected patients who fail standard therapy 8
The American Gastroenterological Association suggests that for GERD without erosive disease, standard-dose PPIs are appropriate first-line; reserve higher-potency agents for documented failures of twice-daily standard PPIs 8
Proton pump inhibitors reduce rebleeding by 57% (OR 0.43, 95% CI 0.29-0.63) and mortality by 44% (OR 0.56, 95% CI 0.34-0.94) compared to placebo/H2-antagonists after endoscopic therapy for upper GI bleeding with high-risk stigmata 9
The American Gastroenterological Association guidance emphasizes that even modest clinical superiority may not justify routine first-line use of the most expensive agents when double-dose standard PPIs can achieve similar outcomes, and potassium-competitive acid blockers (P-CABs) should generally not be used as first-line therapy due to markedly higher costs, access barriers, and limited long-term safety data 8

H2-receptor antagonists like famotidine may be considered as an alternative to PPIs in patients taking clopidogrel 10